Weight-loss drug developer Metsera raises $275 million in US IPO
(Reuters) -Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed ...
BioPharma Dive3h
Metsera, Maze secure combined $415 million in IPOs
The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...
Included Health filed to go public for a 2022 IPO that never happened. Now, it's private, profitable, and bigger than before.
Included Health filed its S-1 for an IPO that never happened. Its CEO said the company went heads-down to reach profitability and sales growth.
IPO lock-in expiry: Shares of 82 companies worth $32 billion set to hit the market by April
Over $32 billion worth of shares from 82 companies will become tradable from January to April 2025 as lock-in periods end.